Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Business Wire3d
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...
Morningstar3d
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for ...
HC Wainwright Has Optimistic Outlook of ATRA Q3 Earnings
HC Wainwright increased their Q3 2025 earnings estimates for shares of Atara Biotherapeutics in a report released on Tuesday, ...
HC Wainwright Issues Optimistic Outlook for ATRA Earnings
Equities researchers at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Atara ...
Investing14d
Atara stock holds Neutral rating after workforce cut
Tuesday, H.C. Wainwright maintained its Neutral stance on Atara Biotherapeutics stock (NASDAQ:ATRA), following the company's announcement of a significant workforce reduction. According to ...
Morningstar6d
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are ...